Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures

Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conservation toward bilateral surgical procedures.

Feb

Today In Oncology

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Related Videos

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Charles E. Geyer, Jr, MD, FACP, on the SOFT Trial

Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer

Harry D. Bear, MD, PhD, on the NSABP B-40 Study in HER2-Negative Breast Cancer

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures

Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

World Cancer Day 2026 UICCs Campaign United by Unique

Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer

American College of Surgeons Publishes Annual NCDB Report